IMPORTANT: Read the Prep & Injection Guide for proper reconstitution, syringe sizing, and injection protocols. Mistakes here can compromise your research.
Tesofensine (Oral)
Tesofensine is a centrally acting triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for neurodegenerative disease and later studied for obesity due to appetite suppression. It is not a peptide and is not approved in many jurisdictions.
Dosing Protocols
Clinical obesity studies evaluated ~0.25–1.0 mg orally once daily, with higher doses increasing side effects. Research cycles commonly 8–12 weeks with monitoring.
Benefits
- Appetite suppression and reduced caloric intake
- Clinically studied for weight loss in obesity
- May improve triglycerides and metabolic markers secondary to weight loss
- Potential improvement in energy levels/drive in some subjects (dopaminergic/noradrenergic)
- Investigated for effects on attention/motivation (theoretical)
Mechanism of Action
Inhibits presynaptic reuptake of serotonin (5‑HT), norepinephrine (NE), and dopamine (DA), increasing synaptic concentrations and enhancing hypothalamic satiety signaling while reducing hunger. Sympathomimetic effects can increase heart rate and blood pressure.
Side Effects
- Increased heart rate
- Elevated blood pressure
- Insomnia
- Dry mouth
- Constipation
- Anxiety/jitteriness
- Headache
- Nausea
Side Effect Management
- Dose in the morning to reduce insomnia
- Monitor BP/HR regularly
- Increase fiber/hydration for constipation
- Avoid combining with other stimulants
- Discontinue if sustained tachycardia or hypertension occurs
Contraindications
- Cardiovascular disease, uncontrolled hypertension
- Arrhythmias
- Anxiety disorders/panic disorder (may worsen)
- Use with MAOIs/serotonergic drugs (serotonin syndrome risk)
- Pregnancy/breastfeeding
- History of substance use disorder (dopaminergic reinforcement risk)
Research Citations
PubMed/DOI-linked citations for verification. Many studies are preclinical (animal/in-vitro) or early clinical.
- Astrup A et al. Tesofensine, a novel triple monoamine reuptake inhibitor, produces weight loss in obese subjects: a randomized trial. DOI Link
- Finer N et al. Safety and efficacy of tesofensine in obesity (follow-up analyses). DOI Link
- Stahl SM. Mechanism of action of triple reuptake inhibitors (review). DOI Link
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).
